Joseph A. Sparano, MD; Lawrence J. Brandt, MD; Janice P. Dutcher, MD; Jon S. Dubois, MD; Michael B. Atkins, MD
Two patients treated with high-dose interleukin-2 (IL-2), who had a history of Crohn disease that was clinically quiescent for 4 and 9 years before therapy, developed symptomatic reactivation of Crohn disease requiring surgical intervention. At laparotomy, both patients had histologic evidence of active Crohn disease. One patient had previously received another cytokine, -interferon-, without disease reactivation, suggesting that this effect was specific for IL-2. The striking temporal relation between the administration of IL-2 and the symptomatic reactivation of previously quiescent Crohn disease suggests the need to carefully evaluate patients with a history of inflammatory bowel disease who are considered for IL-2 therapy and provides evidence supporting an important role for IL-2 in the pathogenesis of Crohn disease.
Sparano JA, Brandt LJ, Dutcher JP, Dubois JS, Atkins MB. Symptomatic Exacerbation of Crohn Disease after Treatment with High-Dose Interleukin-2. Ann Intern Med. ;118:617–618. doi: 10.7326/0003-4819-118-8-199304150-00007
Download citation file:
Published: Ann Intern Med. 1993;118(8):617-618.
Gastroenterology/Hepatology, Inflammatory Bowel Disease.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use